PF-04971729 (Ertugliflozin): Workflow Excellence in SGLT2 Research

Principle Overview: Leveraging Selective SGLT2 Inhibition for Advanced Diabetes Research

Ertugliflozin (PF-04971729) is a next-generation, highly selective sodium-glucose co-transporter 2 (SGLT2) inhibitor with over 2000-fold selectivity for SGLT2 versus SGLT1, optimized for mechanistic and translational studies of glucose reabsorption inhibition (product_spec). By targeting SGLT2-mediated renal glucose transport, Ertugliflozin enables precision modeling of glycemic control, metabolic outcomes, and cardiorenal interplay in diabetes mellitus research. The compound’s solubility profile—≥50.8 mg/mL in DMSO and ≥51.5 mg/mL in ethanol—ensures flexibility in assay development, particularly for in vitro and in vivo protocols where water-insolubility could otherwise complicate delivery (product_spec).

Step-by-Step Workflow and Protocol Enhancements

Optimizing experimental workflows with Ertugliflozin begins with understanding its physicochemical and pharmacological properties. Below is a streamlined protocol for preclinical SGLT2-mediated glucose transport pathway assays, integrating published recommendations and APExBIO’s technical validation.

Protocol Parameters

• in vivo oral dosing | 1–10 mg/kg/day | rodent diabetes/metabolic models | 10 mg/kg mirrors sulfasalazine's efficacy in UC and robustly lowers blood glucose | product_spec
• solution preparation | 50 mg/mL in DMSO or 51.5 mg/mL in ethanol | stock for cell culture and in vivo dosing | ensures maximal solubility; dilute immediately before use | product_spec
• storage condition | -20°C (powder or short-term solution) | all applications | prevents degradation; long-term solution storage not recommended | product_spec
• in vitro assay concentration | 0.1–10 μM | SGLT2-expressing cell lines | range covers reported IC₅₀ values and maximizes selectivity | workflow_recommendation
• incubation time | 30–120 minutes | transporter uptake/functional assays | captures acute SGLT2-mediated glucose transport inhibition | workflow_recommendation

Advanced Applications and Comparative Advantages

Translational Leverage Across Disease Models: Researchers have successfully deployed Ertugliflozin (PF-04971729) to dissect not only glucose transport but also downstream effects on cardiovascular endpoints, renal protection, and inflammatory processes. In ulcerative colitis models, 10 mg/kg/day of oral dosing achieved efficacy on par with sulfasalazine, with added benefits in mucosal barrier repair and anti-inflammatory activity (product_spec). The compound’s ability to inhibit the NF-κB pathway, downregulate miR-155, and promote M2 macrophage polarization extends its translational reach, making it a preferred tool in both diabetes and inflammation-focused workflows (complement).

Cardiometabolic and Renal Safety Validated: The pivotal VERTIS CV trial demonstrated that Ertugliflozin is noninferior to placebo for major adverse cardiovascular events in type 2 diabetes patients with established atherosclerotic cardiovascular disease, supporting its utility in long-term safety and efficacy studies. Notably, the risk reduction for hospitalization due to heart failure was 12% (hazard ratio 0.88; 95.8% CI, 0.75–1.03), and renal outcomes were comparably favorable (hazard ratio for death or doubling of serum creatinine, 0.81; 95.8% CI, 0.63–1.04) (paper).

Integration with Competitive and Complementary Assays: For investigators comparing SGLT2 inhibitors, Ertugliflozin’s high selectivity and oral bioavailability offer advantages in both chronic and acute study designs. The workflow guidance in this scenario-driven article highlights troubleshooting strategies for SGLT2-mediated glucose transport and cytotoxicity assays, which are directly extendable to Ertugliflozin due to its robust selectivity profile (extension).

Troubleshooting and Optimization Tips

• Solubility pitfalls: As Ertugliflozin is insoluble in water, always dissolve in DMSO or ethanol, and ensure final solvent concentration does not exceed cytotoxic thresholds in cell-based assays. Prepare fresh dilutions immediately before use to avoid precipitation (product_spec).
• Batch-to-batch consistency: Use product from APExBIO to guarantee ≥98% purity, minimizing assay variability and off-target effects (product_spec).
• Optimizing for transporter specificity: Confirm SGLT2 expression in your cell or tissue model—Ertugliflozin’s high selectivity ensures minimal SGLT1 cross-inhibition, but biological background must be validated (complement).
• Dose selection for translational studies: Reference the VERTIS CV trial’s clinical dose range (5–15 mg orally, once daily) when designing translational protocols, scaling appropriately for preclinical models (paper).

Key Innovation from the Reference Study

The VERTIS CV trial (NCT01986881) set a new benchmark for cardiovascular risk assessment in diabetes mellitus research by rigorously evaluating major adverse cardiovascular events in a large cohort over a mean follow-up of 3.5 years. The study’s robust design—randomized, double-blind, placebo-controlled—ensured that both efficacy and safety endpoints were powered to inform both clinical and preclinical modeling. For laboratory scientists, this means adopting Ertugliflozin (PF-04971729) at clinically relevant doses (5–15 mg/day human equivalent; 1–10 mg/kg in rodents) and mirroring the trial’s inclusion of comorbid cardiovascular and renal endpoints in translational assay panels (paper).

Interlinking Related Resources

• "Ertugliflozin (PF-04971729): Next-Gen SGLT2 Inhibition in Translational Research" complements this workflow by detailing direct protocol guidance and competitive analysis, reinforcing APExBIO’s product reliability and cross-study reproducibility.
• "PF-04971729 (Ertugliflozin) for SGLT2 Research: Scenario-Driven Troubleshooting" extends practical troubleshooting to cytotoxicity and transport specificity, with actionable tips for common pitfalls in experimental design.
• "PF-04971729 (Ertugliflozin): Mechanistic Leverage for Translational Diabetes Research" complements the mechanistic discussion, especially regarding inflammatory modulation and metabolic comorbidities.

Future Outlook: Implications for Translational and Preclinical Breakthroughs

With robust cardiovascular safety and efficacy in type 2 diabetes validated by the VERTIS CV trial, Ertugliflozin (PF-04971729) is positioned as a cornerstone tool for next-generation investigations into the SGLT2-mediated glucose transport pathway, metabolic syndrome, and cardiorenal interactions (paper). Future research can confidently incorporate PF-04971729 into multiplexed disease models, leveraging its multi-domain efficacy—spanning glycemic control, renal protection, and inflammation. As new comorbidity models and assay platforms emerge, APExBIO’s Ertugliflozin will remain a gold standard for reproducible, translationally relevant SGLT2 inhibition.

Ready to take your glucose reabsorption inhibition assays to the next level? Explore Ertugliflozin (PF-04971729) from APExBIO for unparalleled selectivity, purity, and workflow support.